Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review (Business Wire)

UF Innovate | Sid Martin alumni startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential treatment of OM following a positive review by an independent Data Safety Monitoring Board (DSMB).

“Based on the DSMB’s positive review, and using funds recently raised through a public offering, we are now expanding our Phase 2 trial to up to 45 additional centers in the US and EU in order to rapidly accelerate patient enrollment,” stated Alan Joslyn, president and CEO of Oragenics, Inc. “With our reinforced cash position, we look forward to completing the trial next year while concurrently advancing our lantibiotic program.”

Learn more about Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review.

X